The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: A double-blind placebo-controlled trial

Journal of Neural Transmission

Volumn 119, Issue 11, 2012, Pages 1417-1423

  Green, Tamar ^a,b,c   Steingart, Lital ^a,c,d   Frisch, Amos ^a   Zarchi, Omer ^a,c   Weizman, Abraham ^a,e   Gothelf, Doron ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b BEER YAAKOV MENTAL HEALTH CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^e GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

22q11.2DS; Attention deficit hyperactivity disorder; Depressive disorder; Dopamine COMT; S adenosyl L methionine

Indexed keywords

CALCIUM; CARBAMAZEPINE; CATECHOL METHYLTRANSFERASE; CLONAZEPAM; ETIRACETAM; FLUPHENAZINE DECANOATE; LAMOTRIGINE; LEVOTHYROXINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; RISPERIDONE; S ADENOSYLMETHIONINE; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHROMOSOME DELETION; CHROMOSOME DELETION 22Q11.2; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTHYMIA; ENZYME ACTIVITY; FEMALE; FLU LIKE SYNDROME; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL SYMPTOM; GENE DOSAGE; HAPLOINSUFFICIENCY; HUMAN; INCREASED APPETITE; MAJOR DEPRESSION; MALE; MANIA; MENTAL DISEASE; MOOD; MORBIDITY; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CROSS-OVER STUDIES; DEPRESSIVE DISORDER, MAJOR; DIGEORGE SYNDROME; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PSYCHIATRIC STATUS RATING SCALES; S-ADENOSYLMETHIONINE; YOUNG ADULT;

EID: 84869495800     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0831-x     Document Type: Article

References (32)

1. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ 3rd, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M (2004) S-Adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol 24(6):661-664
2. Aneja A, Fremont WP, Antshel KM, Faraone SV, AbdulSabur N, Higgins AM, Shprintzen R, Kates WR (2007) Manic symptoms and behavioral dysregulation in youth with velocardiofacial syndrome (22q11.2 deletion syndrome). J Child Adolesc Psychopharmacol 17(1):105-114
3. Antshel KM, Shprintzen R, Fremont W, Higgins AM, Faraone SV, Kates WR (2010) Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry 49(4):333-344
4. Balcioglu A, Ren JQ, McCarthy D, Spencer TJ, Biederman J, Bhide PG (2009) Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Neuropharmacology 57(7-8):687-693
5. Bassett AS et al (1998) 22q11 Deletion syndrome in adults with schizophrenia. Am J Med Genet 81:328-337
6. Bottiglieri T,Godfrey P, Flynn T, CarneyMW, Toone BK, ReynoldsEH (1990) Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53(12):1096-1098
7. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM (2003) A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 112(1 Pt 1):101-107
8. Carney MW, Chary TK, Bottiglieri T, Reynolds EH (1989) The switch mechanism and the bipolar/unipolar dichotomy. Br J Psychiatry 154:48-51
9. Cohen SM, Nichols A, Wyatt R, Pollin W (1974) The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 8(2):209-225
10. Diamond A, Briand L, Fossella J, Gehlbach L (2004) Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry 161(1):125-132
11. Diamond A, Barnett WS, Thomas J, Munro S (2007) Preschool program improves cognitive control. Science 318(5855):1387-1388
12. DuPauI GAA, Power T, Reid R, Ikeda M, McGoey K (1998) Parent ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. J Psychopathol Behav Assess 20(1):83-102
13. Feinstein C, Eliez S, Blasey C, Reiss AL (2002) Psychiatric disorders and behavioral problems in children with velocardiofacial syndrome: usefulness as phenotypic indicators of schizophrenia risk. Biol Psychiatry 51(4):312-318
14. First M, Gibbon M, Spitezer R, Williams J (1996) User's guide for the structural clinical interview for DSM-IV Axis I disorders: research version. Biometric Research, New York
15. Goren JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM (2004) Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 24(11):1501-1507
16. Gothelf D, Eliez S, Thompson T, Hinard C, Penniman L, Feinstein C, Kwon H, Jin S, Jo B, Antonarakis SE, Morris MA, Reiss AL (2005) COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8(11):1500-1502
17. Gothelf D, Feinstein C, Thompson T, Gu E, Penniman L, Van Stone E, Kwon H, Eliez S, Reiss AL (2007) Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 164(4):663-669
18. Green T, Gothelf D, Glaser B, Debbane M, Frisch A, Kotler M, Weizman A, Eliez S (2009) Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry 48(11):1060-1068
19. Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, Zarchi O, Weizman A, Gothelf D (2011) The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 21(6):589-595
20. Hedges DW, Brown BL, Shwalb DA (2009) A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum Psychopharmacol 24(1):35-40
21. Lamango NS, Charlton CG (2000) Farnesyl-L-cysteine analogs block SAM-induced Parkinson's disease-like symptoms in rats. Pharmacol Biochem Behav 66(4):841-849
22. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI (2011) Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur Psychiatry(in press)
23. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J (1995) Kinetics of human soluble and membranebound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34(13):4202-4210
24. Mischoulon D, Fava M (2002) Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 76(5):1158S-1161S
25. Papakostas GI (2009) Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry 70 (Suppl 5):18-22
26. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M (2010) S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167(8):942-948
27. Shanee N, Apter A, Weizman A (1997) Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Israel J Psychiatry Related Sci 34(3):179-186
28. Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, Lachman H, Weizman A (2009) Improvement of aggressive behavior and quality of life impairment following S-adenosylmethionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 19(1):14-22
29. van Amelsvoort T, Henry J, Morris R, Owen M, Linszen D, Murphy K, Murphy D (2004) Cognitive deficits associated with schizophrenia in velo-cardio-facial syndrome. Schizophr Res 70(2-3):223-232
30. Wechsler D (1991) Wechsler Intelligence Scale for children, 3rd edn manual, Psychological Corp, San antonio, TX
31. Werner P, Di Rocco A, Prikhojan A, Rempel N, Bottiglieri T, Bressman S, Yahr MD (2001) COMT-dependent protection of dopaminergic neurons by methionine, dimethionine and S-adenosylmethionine (SAM) against L-dopa toxicity in vitro. Brain Res 893(1-2):278-281
32. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435